In addition, an accurate evaluation of the genealogical trees of breast/ovarian cancer BRCA1‐2 patients with PVs allows the detection of men who are potentially carriers of DRG PVs and consequently enrol them in a dedicated screening, which is currently not so defined compared to the screening for breast/ovarian cancers in females. This evidence concerns the gene BRCA1 and ovarian carcinoma.